Worries on drug research
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A House of Commons select committee will this afternoon question representatives of Glaxo and Wellcome about the implications for scientific research of the proposed merger between the two drugs groups.
Wellcome's largest shareholder, the Wellcome Trust, will also face questions from the Commons science and technology committee. The trust received High Court approval last week to sell its 39.5 per cent stake to Glaxo as part of the £9bn bid for Wellcome.
Sir Giles Shaw, the Tory chairman of the committee will take evidence on the extent to which a combination of Glaxo and Wellcome would affect research by the two companies, which between them spent more than £1bn on R&D last year.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments